[Federal Register Volume 62, Number 246 (Tuesday, December 23, 1997)]
[Notices]
[Pages 67088-67089]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-33384]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Pharmaceutical
Compositions And Methods For Treatment of Hyperproliferative Epithelial
Skin Diseases and Cancer
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice in accordance with 35 U.S.C. Sec. 209(c)(1) and
37 CFR 404.7(a)(1)(I) that the National Institutes of Health,
Department of Health and Human Services, is contemplating the grant of
an exclusive worldwide license to practice the inventions embodied in
the U.S. Patent Application SN 07/677,429 ``Pharmaceutical Compositions
And Methods For Preventing Skin Tumor Formation And Causing Regression
Of Existing Tumors'' filed 3/29/91 and U.S. Patent Application SN 08/
389,845 ``Method For The Treatment Of Hyperproliferative Epithelial
Skin Disease By Topical Application Of Hydroxylated Aromatic Protein *
* *'' filed 2/2/95 now U.S. Patent 5,610,185 issued 3/11/97 to Nascent
Pharmaceuticals, L.L.C. of San Francisco, CA. The patent rights in this
invention have been assigned to the United States of America.
The prospective exclusive license field of use may be limited to:
Therapeutics for treatment and prevention of various hyperproliferative
skin diseases in humans.
DATE: Only written comments and/or applications for a license which are
received by NIH on or before March 23, 1998 will be considered.
ADDRESS: Requests for copies of the patent or patent application,
inquiries, comments and other materials relating to the contemplated
licenses should be directed to: Joseph G. Contrera, M.S., J.D.,
Technology Licensing Specialist, Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; Telephone: (301)
[[Page 67089]]
496-7056 ext. 244; Facsimile (301) 402-0220. A signed Confidentiality
Agreement will be required to receive copies of the patent application.
SUPPLEMENTARY INFORMATION:
The 07/677,429 (`429) invention describes the use of Staurosporine and
closely related compounds in treating precancerous conditions of the
skin by topical application. Staurosporine has been known for at least
a decade as an inhibitor of protein kinase C, a major cellular enzyme
involved in cell signalling and second messenger systems.
The 08/389,845 (`845) invention is directed towards a method of
treating hyperproliferative epithelial cell lesions by topical
application of hydroxylated aromatic protein cross-linking compounds
which are derived from cinnamic acid. These compounds utilize dual
methods of action, that is, growth inhibition and protein cross
linking. Both the `429 and `845 inventions may be applied towards a
wide range of skin disorders, including warts, cervical tumors, pre-
malignant lesions, basal carcinomas and squamous carcinomas.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. Sec. 209 and 37 CFR
404.7. The prospective exclusive license may be granted unless within
ninety (90) days from the date of this published notice, NIH receives
written evidence and argument that establishes that the grant of the
license would not be consistent with the requirements of 35 U.S.C.
Sec. 209 and 37 CFR 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated licenses. Comments and objections submitted to this notice
will not be made available for public inspection and, to the extent
permitted by law, will not be released under the Freedom of Information
Act, 5 U.S.C. Sec. 552.
Dated: December 9, 1997.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 97-33384 Filed 12-22-97; 8:45 am]
BILLING CODE 4140-01-M
